SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility.

Co-authored by SOLVD Health scientists in collaboration with San Raffaele Roma Open University and CEINGE–Biotecnologie Avanzate in Naples, Italy, the article, “Establishing Best Practices for Clinical GWAS: Tackling Imputation and Data Quality Challenges,” directly supports the scientific foundation behind AvertD, SOLVD Health’s FDA-approved genetic test for assessing the risk of developing opioid use disorder (OUD). As AvertD expands its clinical reach, the standards outlined in this paper demonstrate the rigor behind its development and the company’s commitment to responsible innovation in genomic medicine.

“There is a growing need to establish clear standards around the preparation and use of genomic data,” said Dr. Keri Donaldson, Founder and President of SOLVD Health. “This work brings those standards into focus and supports more consistent, reliable application of genetic information in clinical settings.”

"Genotype imputation is crucial for translating GWAS discoveries into actionable clinical insights,” said Dr. Valeria D'Argenio, Professor at San Raffaele Roma Open University and CEINGE–Biotecnologie Avanzate Principal Investigator and Head of Molecular Diagnostics. “By defining a rigorous, evidence-based framework spanning quality control, cross-population validation and ethical equity, we provide the community with a clear road map for minimizing error, maximizing reproducibility and ensuring that the benefits of precision medicine reach all patient populations.”

The article outlines best practices for clinical GWAS implementation, including: direct genotyping of clinically actionable variants, transparent reporting of imputation quality metrics, cross-population validation, ancestry-matched reference panels, rigorous quality control, ethical and equity safeguards, and global collaboration.

“We are committed to setting a high bar for how genetic insights are used in medicine,” said Dr. Donaldson. “This article reflects this notion and reinforces the foundation on which AvertD was developed, and how we approach every solution we bring into clinical practice.”

Read the full article: Establishing Best Practices for Clinical GWAS: Tackling Imputation and Data Quality Challenges

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about SOLVD Health, visit www.solvdhealth.com.